After bad results, Ajanta Pharma continues to disappoint with their guidance.
1-2 product launches vs earlier guidance of 3-4
EBITDA margin guidance of <25% vs earlier guidance of 25-27%
Capex of Rs. 150 crores vs earlier guidance of Rs. 200 crores.
| Subscribe To Our Free Newsletter |
